AEterna/Spectrum compound begins phase II prostate trial
D-63153 is a fourth generation luteinizing hormone-releasing hormone (LHRH) antagonist. The trial will evaluate the efficacy of D-63153 as measured by its effects on clinical signs and symptoms
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.